Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Other Non Operating Income (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Other Non Operating Income for 16 consecutive years, with -$12.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 204.24% year-over-year to -$12.5 million, compared with a TTM value of $24.4 million through Sep 2025, up 264.57%, and an annual FY2023 reading of -$15.9 million, down 480.41% over the prior year.
  • Other Non Operating Income was -$12.5 million for Q4 2025 at Amicus Therapeutics, down from $10.9 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $13.6 million in Q3 2022 and bottomed at -$12.5 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is $440263.2, with a median of $237000.0 recorded in 2021.
  • The sharpest move saw Other Non Operating Income soared 5652.74% in 2022, then plummeted 412.2% in 2023.
  • Year by year, Other Non Operating Income stood at $237000.0 in 2021, then surged by 1662.03% to $4.2 million in 2022, then plummeted by 168.94% to -$2.9 million in 2023, then surged by 514.94% to $11.9 million in 2024, then crashed by 204.24% to -$12.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for FOLD at -$12.5 million in Q4 2025, $10.9 million in Q3 2025, and $1.0 million in Q2 2025.